SCHEMBL5156718

SCHEMBL5156718

COc1ccc(C2SCC(=O)N2CC(Cc2ccccc2)C2=COCO2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CACNA1B Q00975 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
POLB P06746 1/20 0.39
ALOX15 P16050 1/20 0.39
KCNA5 P22460 2/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HTR7 P34969 1/20 0.37
GFER P55789 1/20 0.37
PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152312 0.87 HCRTR1 (0.46) MEN1KMT2AHCRTR1HCRTR2ALDH1A1
SCHEMBL5155154 0.81 ALDH1A1 (0.42) MEN1KMT2AKDM4ECACNA1BCYP2C19
SCHEMBL5156370 0.80 CACNA1B (0.38) MEN1KMT2AKDM4ECACNA1BPOLB
SCHEMBL5151419 0.78 KMT2A (0.46) MEN1KMT2AMAPTCYP2C19POLB
SCHEMBL5152138 0.78 KMT2A (0.41) MEN1KMT2ACACNA1BPOLBHCRTR1
SCHEMBL5149508 0.77 MEN1 (0.44) MEN1KMT2AKDM4EGAATDP1
SCHEMBL5156971 0.73 KMT2A (0.37) MEN1KMT2AKDM4EGAAL3MBTL1
SCHEMBL747905 0.73 HCRTR1 (0.41) MEN1KMT2AMAPK1KCNA5HCRTR1
SCHEMBL6824250 0.73 CACNA1B (0.61) CACNA1B
SCHEMBL5156712 0.70 GAA (0.60) MEN1KMT2AMAPK1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MEN1 3532/4885KMT2A 4084/4885MAPK1 2974/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885MAPK1 3390/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885MAPK1 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.